'Safety first', says Bharat Biotech amid AstraZeneca row

Bharat Biotech’s indigenously developed Covid-19 vaccine Covaxin was overall found to have “much lower” AEFI (adverse effects following immunisation) rates..

A study from BHU analyzing the lasting impacts of Bharat Biotech's Covaxin found nearly a third of recipients reported adverse events of special interest (AESI)...

Nearly one-third of Covaxin recipients experienced adverse events of special interest within a year, including respiratory, skin, and musculoskeletal issues. The..

UK-based drug major AstraZeneca's decision to withdraw its Covid-19 vaccine globally, days after admitting to side effects, prompted Serum Institute of India to..

SII stopped Covishield extra doses due to lawsuit, disclosed rare Thrombosis. Advocates govt collaboration. AstraZeneca withdraws Vaxzevria marketing..